Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 520 of 6351
-
New device aims to stop deadly postpartum bleeding when drugs fail
Disease control Recruiting nowabnormal bleeding after childbirth. This condition is called abnormal bleeding and becomes a condition known as postpartum hemorrhage (PPH) when worsens. Abnormal bleeding is defined as the loss of more than 500 milliliters (about two cups) of blood after a vaginal birth, or more…
Phase 3 • Sponsor: ResQ Medical Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can targeted exercise programs improve balance in children with cerebral palsy?
Disease control CompletedCerebral palsy (CP) is a group of permanent disorders affecting movement and posture, caused by non-progressive disturbances in the developing fetal or infant brain. Circuit training and task-oriented training are two emerging approaches in pediatric rehabilitation. Circuit tra…
Sponsor: Ibadat International University, Islamabad • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Diabetes remission possible without drugs? new trial investigates lifestyle overhaul
Disease control Not yet recruitingThe purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are: * What proportion of participants …
Sponsor: Parc Sanitari Pere Virgili • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test catches cancer early; drug aims to stop return
Disease control Not yet recruitingThe goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer after curative surgery and standard therapy. The stu…
Phase 2 • Sponsor: Nagoya City University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
High-Tech gait training shows promise for spinal cord injury recovery
Symptom relief Recruiting nowThe goal of this clinical trial is to determine whether combining Functional Electrical Stimulation (FES) with Augmented Reality (AR)-based gait training can improve walking ability in individuals with incomplete spinal cord injury (SCI). The study aims to identify the most effec…
Sponsor: Lahore University of Biological and Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New hope for lung cancer patients Who've run out of options?
Disease control Recruiting nowA Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/o…
Phase 2 • Sponsor: STCube, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Pap smear upgrade? DNA test could spot hidden uterine cancer
Diagnosis Not yet recruitingThe goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer. The main questions it aims to answer are: * What is the sensitivity and specificit…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Promising cocktail aims to save voice boxes in head and neck cancer
Disease control Not yet recruitingAlthough multiple immune-checkpoint inhibitors (ICIs) have demonstrated efficacy in recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M-SCCHN), outcomes in the locally advanced (LA-SCCHN) setting remain suboptimal, and treatment continues to pose a major the…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New mRNA shingles vaccine enters phase 2 trial – could it be a game changer?
Vaccine Not yet recruitingHerpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease bur…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
Breathing without a tube: new strategy aims to speed lung transplant recovery
Disease control Not yet recruitingThe goal of this study is to learn whether a spontaneous-breathing ("tubeless") anesthesia and surgery strategy can improve early recovery and remain safe for adults who receive a lung transplant. This strategy aims to help lung transplant recipients maintain spontaneous breathin…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy aims to shrink lung tumors before surgery
Disease control Recruiting nowThis study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excl…
Phase 2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
Disease control OngoingThis is a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the safety and efficacy in immune thrombocytopenia patients receiving fecal microbiota transplantation
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Brain cancer vaccine trial aims to boost Chemo's punch
Disease control Not yet recruitingThis is a multicenter, open-label, randomized Phase II clinical study designed to evaluate the efficacy and safety of a personalized dendritic cell (DC) vaccine, ZSNeo-DC1.1, in combination with temozolomide (TMZ) as adjuvant therapy in patients with newly diagnosed glioblastoma …
Phase 2 • Sponsor: ZSky Biotech Inc • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-tr…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New trial aims to solve JIA treatment puzzle after first drug fails
Disease control Recruiting nowThis study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 rand…
Phase 3 • Sponsor: Duke University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Phase 1/2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug duo targets advanced skin cancer in promising trial
Disease control Not yet recruitingStudy Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor monotherapy is approximately 30%. The expected ORR for …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can an ancient herbal formula beat antibiotics for urinary infections?
Disease control OngoingThis study intends to conduct a prospective, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Lishi Tonglin Granule (a hospital-formulated innovative prescription) developed in our hospital for alleviating preoperative urinary tract inf…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for rare cancer: virus-based therapy combined with immunotherapy
Disease control Recruiting nowThis is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in particip…
Phase 2 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Promising new shot for bulging eyes moves to final testing
Disease control Recruiting nowThis is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
Phase 3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC